Long‐term outcomes in a 25‐year‐old female affected with lipin‐1 deficiency. Issue 1 (14th March 2019)

• Record Type: Journal Article
• Authors: Stepien, Karolina M.; Schmidt, Wolfgang M.; Bittner, Reginald E.; O'Toole, Orna; McNamara, Brian; Treacy, Eileen P.
• Is Part Of: JIMD reports. Volume 46:Issue 1(2019)
• Page Start: 4
• Page End: 10
• Publication Date: 2019-03-14
• Subjects: lipid myopathy -- lipin‐1 deficiency -- LPIN1 gene -- mutation -- neuropathy -- rhabdomyolysis; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jmd2.12016
• Languages: English
• ISSNs: 2192-8304

Abstract

Abstract: Lipin‐1 is a phosphatidic acid phosphohydrolase (EC 3.1.3.4) that catalyzes the dephosphorylation of phosphatidic acid to diacylglycerol and inorganic phosphate. Deficiency of this enzyme causes potentially fatal severe, recurrent episodes of rhabdomyolysis triggered by infection. The defect has only recently been recognized so little is known about the long‐term outcome in adult patients with this disorder. We report the course and outcome of a 25‐year‐old female patient with lipin‐1 deficiency after a recent episode of rhabdomyolysis requiring intensive care admission with a peak creatine kinase of 500 000 IU/L. One‐year post discharge from intensive care, the patient has residual drop foot bilaterally consistent with bilateral common peroneal neuropathies in addition to a background residual distal myopathy.